About Event

Welcome to the 8th Tumor Models San Francisco Summit

Your Must-Attend Meeting to Welcome 2024!

The Tumor Models San Francisco Summit stands out as the only West Coast industry-led meeting dedicated to defining preclinical modelling approaches, with real-world case studies to support oncology studies that will empower you to accelerate your candidate’s clinical translatability with optimized efficiency, and cost-effectiveness.

With the FDA Modernization Act 2.0 enabling non-animal models to be integrated into drug pipelines and combination regimes gaining approval as targeted therapies, the humanized animal model space is projected to boom to $338 million by 2027. Alongside this growth and the current high rate of attrition in oncology, the need for more clarity on best practice in tumor modelling also increases to ensure you don’t fall behind.

Building on this momentum, the 8th annual event will return to San Francisco in early 2024 to provide an update on tumor model advancements, and how they can complement existing models to increase clinical confidence and clinical relevancy in your candidate. Be part of the dialogue to advance bench-to-bedside development for safe and efficacious candidate selection.

With brand new content covering tumor biology over to therapeutic development, here’s what’s exciting next year:

Drug Developers and Academics – Attendance is Free: We are here to support your translational study and pipeline progression, and offer you the opportunity to meet model providers to select the right platforms and hence, drug developers and researchers are eligible for complimentary passes

Gain in-depth case studies into mouse models and newer models: Delve into strategies to accurately recapitulate tumor heterogeneity and tumor microenvironment from PDX, GEMMs to organoid models

Networking: You will have the unique opportunity to exchange challenges, inspire solutions with leading industry experts across dedicated speed-networking sessions as well as assess the latest technologies over the last 12 months

Novel Topics: Deep dive into brand-new case studies on leveraging tumor models to assess different modalities from ADCs, cell therapies, RNA therapeutics and more through to leveraging spatial technologies to enhance your data readouts

Form meaningful partnerships: Meet and network with selected CROs, model developers and academics to hear their latest platforms that will optimize your workflows

40251 - CompaniesConfirmed (1)